Skip to content

APOTHEEK VERMASSEN

Active Private limited companyfounded 1999active for 27 yearsBaron de Gieylaan 42, 9840 Nazareth-De PinteKBO/BCE: BE 0466.544.066

Lifetime

20 annual accounts with figures on one time axis, 26 filings since 2000
peak of €120,307 in 2008
€118,424▲ 51.4%
lowest -€16,315 in 2022
€81,829▲ 99.1%
peak of €447,235 in 2025
€447,235▲ 22.4%
€92,682▲ 42.6%
peak of 0.9 FTE in 2007
0 FTE 
Board1 name since 1999
1 director
Documentsfilings and deeds
31-08-202631 days late
2025abbreviated format
Gross margin from €78,214 to €118,424Result from €41,110 to €81,829Equity from €365,406 to €447,235Debts from €64,987 to €92,682Cash from €48,521 to €93,542

Key points

from the 2025 annual accounts

Turnover

≈ €560,000 estimated

The accounts state no turnover.

Filings

26 annual accounts since 2000
AprilJune31 JulyOctober200020102020

Nine of the last ten came late. The 2024 accounts came in latest, 40 days after the end of the period.

Position in the sector

82.8%

Higher solvency than 91% of companies in retail trade. The sector median is 36.8%, over 13,303 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 20,149 companies had the same profile as APOTHEEK VERMASSEN has now. Each dot stands for 51 companies, two years later.

95.0%
were still trading
4.7%
stopped another way
0.2%
went bankrupt
  • Small
  • 20 years or older
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,994 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 20,149 companies, not a prediction for APOTHEEK VERMASSEN. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0466544066
(statutory director) and (statutory director) appointed General meeting of 22-08-2022 · Gazette deed
Capital decrease of €153,000 to €18,600 The capital fell from €171,600 to €18,600 · General meeting of 27-11-2018 · Gazette deed
Capital increase of €153,000 to €171,600 After the increase, the capital stands at €171,600 · General meeting of 30-12-2013 · Gazette deed
All 39 events

Comparable companies

same main activity, similar in size and age
Company
APOTHEEK VERMASSEN Nazareth-De Pinte €539,917 €118,424 82.8% 0
Pharmacie de Stoumont Stoumont €574,980 €131,747 9.2% 0
Apotheek Godilo Wevelgem €608,404 €104,532 40.8% 0
APOTHEEK VAN GLABEKE Eeklo €763,636 €104,967 25.4% 0
ST FARMA Ghent €539,584 €104,932 63.8% 0.4
Apotheek Noben Sint-Truiden €536,605 €134,663 30.5% 0
Apotheek Op de Beeck-Neefs Rumst €526,228 €132,550 66.5% 0.2

These companies have the same main activity as APOTHEEK VERMASSEN: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €526,000 and €764,000, founded between 1990 and 2005.

Official details

Source: KBO
Status
Active since 14-07-1999Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730
Establishment unit
2.101.916.7549840 Nazareth-De Pinte, since 29-12-1999
Financial year end
31 December
Peppol
Reachable since 28-11-2025
Company details

Annual accounts 2025

€539,917▲ 25.4%
Filing
Filed on 31-08-2026
Financials

Insights on APOTHEEK VERMASSEN

APOTHEEK VERMASSEN files the abbreviated format. That format states no turnover. The gross margin rose from €94,989 in 2006 to €118,424 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about APOTHEEK VERMASSEN

What is the company number of APOTHEEK VERMASSEN?
The company number of APOTHEEK VERMASSEN is 0466.544.066. The VAT number is the same number with BE in front: BE 0466.544.066.
Where is APOTHEEK VERMASSEN based?
The registered office is at Baron de Gieylaan 42, 9840 Nazareth-De Pinte.Company details
What does APOTHEEK VERMASSEN do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of APOTHEEK VERMASSEN?
APOTHEEK VERMASSEN is a private limited company (BV).
When was APOTHEEK VERMASSEN founded?
APOTHEEK VERMASSEN was founded on 14-07-1999.
Is APOTHEEK VERMASSEN still active?
Yes, APOTHEEK VERMASSEN is an active enterprise in the KBO register.
What is the turnover of APOTHEEK VERMASSEN?
The turnover in financial year 2025 is about €560,000. This figure is estimated from the gross margin of €118,424 and 43 comparable companies (NACE 477). It probably lies between €360,000 and €1.2m.Financials
Is APOTHEEK VERMASSEN profitable?
In financial year 2025, APOTHEEK VERMASSEN made a profit of €81,829.
Where can I find the annual accounts of APOTHEEK VERMASSEN?
APOTHEEK VERMASSEN filed 26 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of APOTHEEK VERMASSEN due?
APOTHEEK VERMASSEN must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.